Skip to main content
Delfa

← All assets

Atabecestat

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

4

Sites

137

Countries

14

Endpoints

56

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 56 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Early Phase 1
1
Phase 1
2
Phase 2
2
Phase 2/3
1

Trials by status

Completed
4
Terminated
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
15
Safety / tolerability / PK
13
Global cognition
10
Fluid / digital biomarkers
7
Other (unclassified)
5
Memory
2
Function / daily living
2
Tau biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 6 of 56 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
EARLYAn Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

Atabecestat

Alzheimer’s disease

Amyloid biomarker required (PET/CSF)Ph 2/3Terminated128Dec 20181results
NCT02260674A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Atabecestat

Alzheimer’s disease

prodromal ADPh 2Completed19Jun 20161
NCT02406027An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Atabecestat

Alzheimer’s disease

Age 50-85Ph 2Terminated17Jun 20181results
NCT01978548A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Atabecestat

Alzheimer’s disease

Amyloid biomarker required (PET/CSF)Ph 1Completed10Apr 20151
NCT03587376Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Atabecestat

Alzheimer’s disease

Age 50-85Early Ph 1Completed5Aug 2018-
NCT02360657Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Atabecestat

Alzheimer’s disease

Age 65-85Ph 1Completed2Sep 20151

Showing 1-6 of 6 trials